Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The intestinal barrier and gut microbiome constitute a complex physiological system that serves as the primary interface between the external environment and the host's internal milieu. The intestinal barrier is a multi-component structure comprising a biochemical mucus layer, a physical epithelial cell layer maintained by tight junction proteins, and a functional immunological layer (Vancamelbeke & Vermeire, 2017, PubMed: 28620435). The gut microbiome is a diverse community of microorganisms that performs essential metabolic functions, such as the fermentation of non-digestible carbohydrates into short-chain fatty acids, and plays a critical role in the maturation of the host immune system (Thursby & Juge, 2017, PubMed: 28533301). Disruptions to this system, characterized by increased intestinal permeability (often termed "leaky gut") and microbial dysbiosis, are linked to various diseases including inflammatory bowel disease (IBD), obesity, type 2 diabetes, and certain autoimmune conditions (Rinninella et al., 2019, PubMed: 30634350). Pharmacological strategies targeting this system range from antibiotics and probiotics that alter microbial composition to biologics and small molecules that reinforce barrier integrity or modulate the mucosal immune response (Ghosh et al., 2020, PubMed: 31913317). For instance, drugs like Rifaximin are used to manage dysbiosis in irritable bowel syndrome, while investigational agents like Larazotide aim to restore tight junction function in Celiac disease (Camilleri, 2019, PubMed: 31076401). This system is increasingly recognized as a key therapeutic axis for systemic health, influencing not only gastrointestinal function but also metabolic and neurological outcomes.
Modulation of microbial diversity, enhancement of epithelial tight junction integrity, and regulation of mucosal immune signaling (Camilleri, 2019, PubMed: 31076401).
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Intestinal barrier and gut microbiome.